One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Spotlight on the September 7 Issue
Merino, Jose G. MD, MPhil; Editor-in-Chief, Neurology(R)
doi : 10.1212/WNL.0000000000012528
Volume 97(10), 7 September 2021, p 461-462
Antibodies to LRP4 and Agrin Are Pathogenic in Myasthenia Gravis: At the Junction Where It Happens
Lisak, Robert P. MD, FAAN, FRCP, FANA
doi : 10.1212/WNL.0000000000012471
Volume 97(10), 7 September 2021, p 463-464
Resilience and Resistance in Aging and Alzheimer Disease: Another Step to Fill the Gap Between Clinicians and Researchers
Poggesi, Anna MD, PhD
doi : 10.1212/WNL.0000000000012500
Volume 97(10), 7 September 2021, p 465-466
Characterization of LRP4/Agrin Antibodies From a Patient With Myasthenia Gravis
Yu, Zheng MD, PhD*; Zhang, Meiying MD*; Jing, Hongyang PhD*; Chen, Peng PhD*; Cao, Rangjuan MD; Pan, Jinxiu PhD; Luo, Bin PhD; Yu, Yue; Quarles, Brandy M. MPH; Xiong, Wencheng MD, PhD; Rivner, Michael H. MD; Mei, Lin MD, PhD
doi : 10.1212/WNL.0000000000012463
Volume 97(10), 7 September 2021, p e975-e987
To determine whether human anti-LRP4/agrin antibodies are pathogenic in mice and to investigate underpinning pathogenic mechanisms.
Experience of Community Neurologists Providing Care for Patients With Neurodegenerative Illness During the COVID-19 Pandemic
Ayele, Roman PhD, MPH; Macchi, Zachary A. MD; Dini, Megan MA; Bock, Meredith MD; Katz, Maya MD; Pantilat, Steven Z. MD; Jones, Jacqueline PhD, RN, FAAN; Kluger, Benzi M. MD, MS
doi : 10.1212/WNL.0000000000012363
Volume 97(10), 7 September 2021, p e988-e995
Health care delivery systems transformed rapidly at the beginning of the coronavirus disease 2019 (COVID-19) pandemic to slow the spread of the virus while identifying novel methods for providing care. In many ways, the pandemic affected both persons with neurologic illness and neurologists. This study describes the perspectives and experiences of community neurologists providing care for patients with neurodegenerative illnesses during the COVID-19 pandemic.
Brain Processing of Visual Self-Motion Stimuli in Patients With Migraine: An fMRI Study
Carvalho, Gabriela F. PhD*; Mehnert, Jan PhD*; Basedau, Hauke MD; Luedtke, Kerstin PhD; May, Arne MD, PhD
doi : 10.1212/WNL.0000000000012443
Volume 97(10), 7 September 2021, p e996-e1006
To investigate the behavioral and neuronal responses of patients with migraine to a visual simulation of self-motion through a virtual roller coaster ride in comparison to controls.
Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease
Prasuhn, Jannik MD; Prasuhn, Michelle MD; Fellbrich, Anja PhD; Strautz, Robert MD; Lemmer, Felicitas MD; Dreischmeier, Shalida MD; Kasten, Meike MD; Munte, Thomas F. MD; Hanssen, Henrike MD; Heldmann, Marcus PhD; Bruggemann, Norbert MD
doi : 10.1212/WNL.0000000000012444
Volume 97(10), 7 September 2021, p e1007-e1016
To investigate the contribution of substantia nigra (SN) and locus coeruleus (LC) pathology to clinical signs and symptoms in Parkinson disease (PD) by applying neuromelanin-weighted imaging.
[18F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
Wolters, Emma E. MD, PhD; Papma, Janne M. PhD; Verfaillie, Sander C.J. PhD; Visser, Denise MSc; Weltings, Emma MSc; Groot, Colin PhD; van der Ende, Emma L. MD; Giannini, Lucia A.A. MD; Tuncel, Hayel MSc; Timmers, Tessa MD, PhD; Boellaard, Ronald PhD; Yaqub, Maqsood PhD; van Assema, Danielle M.E. MD, PhD; Kuijper, Dennis A. MSc; Segbers, Marcel MSc; Rozemuller, Annemieke J.M. MD, PhD; Barkhof, Frederik MD, PhD; Windhorst, Albert D. PhD; van der Flier, Wiesje M. PhD; Pijnenburg, Yolande A.L. MD, PhD; Scheltens, Philip MD, PhD; van Berckel, Bart N.M. MD, PhD; van Swieten, John C. MD, PhD; Ossenkoppele, Rik PhD; Seelaar, Harro MD, PhD
doi : 10.1212/WNL.0000000000012448
Volume 97(10), 7 September 2021, p e1017-e1030
To assess the [18F]flortaucipir binding distribution across MAPT mutations in presymptomatic and symptomatic carriers.
Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months
Matar, Elie MD; White, Simon R. PhD; Taylor, John-Paul MD, PhD; Thomas, Alan MD, PhD; McKeith, Ian G. MD, FMedSci; Kane, Joseph P.M. PhD; Surendranathan, Ajenthan MD; Halliday, Glenda M. PhD; Lewis, Simon J.G. MD, PhD; O'Brien, John T. DM, FRCPsych
doi : 10.1212/WNL.0000000000012450
Volume 97(10), 7 September 2021, p e1031-e1040
This study aimed to quantify the trajectory and magnitude of change of the key clinical features and corresponding symptom domains of dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD), including global cognition, parkinsonism, recurrent visual hallucinations, cognitive fluctuations, and sleep disturbance.
Long-term Dietary Flavonoid Intake and Subjective Cognitive Decline in US Men and Women
Yeh, Tian-Shin MD, PhD; Yuan, Changzheng ScD; Ascherio, Alberto MD, DrPH; Rosner, Bernard A. PhD; Willett, Walter C. MD, DrPH; Blacker, Deborah MD, ScD
doi : 10.1212/WNL.0000000000012454
Volume 97(10), 7 September 2021, p e1041-e1056
To prospectively examine the associations between long-term dietary flavonoids and subjective cognitive decline (SCD).
Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis
Bocancea, Diana I. MSc; van Loenhoud, Anna C. PhD; Groot, Colin PhD; Barkhof, Frederik MD, PhD; van der Flier, Wiesje M. PhD; Ossenkoppele, Rik PhD
doi : 10.1212/WNL.0000000000012499
Volume 97(10), 7 September 2021, p 474-488
There is a lack of consensus on how to optimally define and measure resistance and resilience in brain and cognitive aging. Residual methods use residuals from regression analysis to quantify the capacity to avoid (resistance) or cope (resilience) "better or worse than expected" given a certain level of risk or cerebral damage. We reviewed the rapidly growing literature on residual methods in the context of aging and Alzheimer disease (AD) and performed meta-analyses to investigate associations of residual method-based resilience and resistance measures with longitudinal cognitive and clinical outcomes.
American Academy of Neurology Code of Professional Conduct
Russell, James A. DO, MS; Hutchins, John C. JD; Epstein, Leon G. MD; on behalf of the AAN Ethics, Law, and Humanities Committee
doi : 10.1212/WNL.0000000000012447
Volume 97(10), 7 September 2021, p 489-495
Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials
Grill, Joshua D. PhD; Karlawish, Jason MD
doi : 10.1212/WNL.0000000000012329
Volume 97(10), 7 September 2021, p 496-500
The goal of clinical research is to improve clinical practice. In progressive neurodegenerative conditions without any disease-slowing therapies, this will result in eventual approval of a first disease-modifying treatment. Clinical trials will still be needed to discover treatments that are more effective, safer, or more convenient. This will generate controversies over how to design these trials; specifically, controversies about the use of a placebo control. We consider ethical guidance for these studies with attention to 3 designs: placebo-controlled trials in the absence of the new drug, placebo-controlled trials with the approved drug as background therapy, and trials with the new drug as an active control. To understand the practical implications of these designs, we examine experiences in drug development in multiple sclerosis. We conclude by contemplating the future of clinical trials in Alzheimer disease.
Carbamazepine-Induced Acute Alopecia Areata
Rathore, Chaturbhuj MD; Rawat, Kalu Singh MD; Prakash, Sanjay MD; Rana, Kaushik MD
doi : 10.1212/WNL.0000000000012387
Volume 97(10), 7 September 2021, p 501-502
Clinical Reasoning: A 40-Year-Old Woman With Scapular Winging and Dysphonia
Aladawi, Mohammad MD; Punsoni, Michael MD; Piccione, Ezequiel MD
doi : 10.1212/WNL.0000000000012179
Volume 97(10), 7 September 2021, p 503-507
Pearls & Oy-sters: Driving Safety in Photosensitive Genetic Generalized Epilepsy
Nasser, Mohamed MD; Sheikh, Zubeda MD
doi : 10.1212/WNL.0000000000012157
Volume 97(10), 7 September 2021, p e1057-e1059
Teaching NeuroImage: Papilledema and Pachymeningitis: An Atypical Presentation of Granulomatosis With Polyangiitis
Radcliffe, Christopher BA; Potnis, Kunal BS; Peng, Teng J. MD; DeCroce-Movson, Eliza MD; Zuchowski, Kathryn MD; Fisayo, Adeniyi MD
doi : 10.1212/WNL.0000000000012156
Volume 97(10), 7 September 2021, p e1060-e1061
Teaching Video NeuroImage: Paroxysmal Nocturnal Dyskinesias: A Characteristic Feature of ADCY5 Mutation
Pringsheim, Tamara M. MD; Cothros, Nicholas MD, PhD; Roze, Emmanuel MD, PhD
doi : 10.1212/WNL.0000000000011920
Volume 97(10), 7 September 2021, p e1062
Editors' Note: CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series
Lewis, Ariane MD; Galetta, Steven MD
doi : 10.1212/WNL.0000000000012526
Volume 97(10), 07 September 2021, p 508
Reader Response: CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series
Kumar, Anand; Lall, Neha
doi : 10.1212/WNL.0000000000012527
Volume 97(10), 07 September 2021, p 508-509
Reader Response: CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series
Brenner, Steven R.
doi : 10.1212/WNL.0000000000012529
Volume 97(10), 07 September 2021, p 509
Author Response: CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series
Eden, Arvid
doi : 10.1212/WNL.0000000000012530
Volume 97(10), 07 September 2021, p 510
Editors' Note: Dietary Antioxidants and the Risk of Parkinson Disease: The Swedish National March Cohort
Lewis, Ariane MD; Galetta, Steven MD
doi : 10.1212/WNL.0000000000012531
Volume 97(10), 07 September 2021, p 510
Reader Response: Dietary Antioxidants and the Risk of Parkinson Disease: The Swedish National March Cohort
Kawada, Tomoyuki
doi : 10.1212/WNL.0000000000012532
Volume 97(10), 07 September 2021, p 511
Author Response: Dietary Antioxidants and the Risk of Parkinson Disease: The Swedish National March Cohort
Hantikainen, Essi; Trolle Lagerros, Ylva; Bonn, Stephanie
doi : 10.1212/WNL.0000000000012533
Volume 97(10), 07 September 2021, p 511-512
Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial
doi : 10.1212/WNL.0000000000012302
Volume 97(10), 7 September 2021, p 512
In Defense of the AAN Position on Lawful Physician-Hastened Death
doi : 10.1212/WNL.0000000000010536
Volume 97(10), 7 September 2021, p 512
